PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. It is currently conducting Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
Stock data | 2024 | Change |
---|---|---|
Price | $4.46 | N/A |
Market Cap | $6.95M | N/A |
Shares Outstanding | 1.56M | N/A |
Employees | 6.00 | N/A |